605199 Hainan Huluwa Pharmaceutical Group
- 10.43
- +0.07+0.68%
Hainan Huluwa Pharmaceutical Group News
Hainan Huluwa Pharmaceutical Group Co., Ltd. received the Shanghai Stock Exchange\'s “Decision on Termination of the Review of Hainan Huluwa Pharmaceutical Group Co., Ltd.\'s Issuance of Convertible Corporate Bonds to Unspecified Targets”
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on holding the 2024 semi-annual results briefing
Hainan Huluwa Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report
Announcement of Resolutions of the Fourth Meeting of the Third Board of Supervisors of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Special report on the storage and actual use of funds raised in the 2024 semi-annual period of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the Fourth Meeting of the Third Board of Directors of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Hainan Huluwa Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report_Summary
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the wholly-owned subsidiary obtaining a drug registration certificate for lacosamide oral solution
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on obtaining a drug registration certificate for inhaled acetylcysteine solution
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on issuing convertible corporate bonds to unspecified targets on the results of the review meeting of the Shanghai Stock Exchange Listing Review Committee
Hainan Huluwa Pharmaceutical Group Co., Ltd. Investor Relations Activity Record Form
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. about its wholly-owned subsidiary obtaining the registration certificate for ibuprofen suspension drip pharmaceutical.
Announcement on Partial Share Pledging by Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the compliance inspection results of pharmaceutical GMP received by its wholly-owned subsidiary.
Announcement on obtaining the approval notice for drug clinical trials by Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement on supplementary pledge of partial shares by the controlling shareholder of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. regarding obtaining the registration certificate of propofol and tenofovir tablets.
Announcement regarding the continued pledge of shares by the actual controlling shareholder of Hainan Huluhwa Pharmaceutical Group Co., Ltd. after the expiration of the pledge.
Announcement from Hainan Huluwa Pharmaceutical Group Co., Ltd. regarding the generic drug consistency evaluation of omeprazole enteric-coated capsules.
Analysis
Price Target
No Data
